Novartis AG vs Unilever PLC: Strategic Comparison
Key Differences at a Glance
| Field | Novartis AG | Unilever PLC |
|---|---|---|
| Revenue | $54.5B | $54.9B |
| Founded | 1996 | 1929 |
| Employees | 75,267 | 125,000 |
| Market Cap | $274.1B | $151.9B |
| Headquarters | Switzerland | United Kingdom |
Quick Stats Comparison
| Metric | Novartis AG | Unilever PLC |
|---|---|---|
| Revenue | $54.5B | $54.9B |
| Founded | 1996 | 1929 |
| Headquarters | Basel, Switzerland | London, United Kingdom |
| Market Cap | $274.1B | $151.9B |
| Employees | 75,267 | 125,000 |
Novartis AG Revenue vs Unilever PLC Revenue — Year by Year
| Year | Novartis AG | Unilever PLC | Leader |
|---|---|---|---|
| 2025 | $54.5B | $54.9B | Unilever PLC |
| 2024 | $50.3B | $66.1B | Unilever PLC |
| 2023 | $45.4B | $64.8B | Unilever PLC |
Business Model Breakdown
Overview: Novartis AG vs Unilever PLC
This in-depth comparison examines Novartis AG and Unilever PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating Unilever PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and Unilever PLC is widest.
On the headline numbers, Novartis AG reports annual revenue of $54.5B against $54.9B for Unilever PLC, while their respective market capitalizations stand at $274.1B and $151.9B. Novartis AG is headquartered in Switzerland and Unilever PLC operates from United Kingdom, and those different home markets shape how each company competes.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Unilever PLC: Unilever used to be described by breadth: hundreds of brands, many categories, many countries. The current strategy is the opposite: fewer brands, clearer ownership, more disciplined capital allocation, and a portfolio tilted toward higher-growth personal care and beauty.
Business Models: How Novartis AG and Unilever PLC Make Money
Novartis AG and Unilever PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and Unilever PLC.
Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Unilever PLC business model: Unilever makes money by building and distributing branded consumer products through supermarkets, drugstores, convenience channels, emerging-market distributors, e-commerce, foodservice, and direct or prestige beauty channels. Scale in procurement, manufacturing, media buying, and route-to-market supports margins.
Competitive Advantage: Novartis AG vs Unilever PLC
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of Unilever PLC.
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Unilever PLC competitive advantage: Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.
Growth Strategy: Where Novartis AG and Unilever PLC Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and Unilever PLC each plan to expand from here.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Unilever PLC growth strategy: Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.
Financial Picture: Novartis AG vs Unilever PLC
A closer look at the financial trajectory of Novartis AG and Unilever PLC rounds out the comparison.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
Unilever PLC: Unilever's 2025 reported turnover was EUR 50.5 billion on a continuing-operations basis after Ice Cream was treated as discontinued. Underlying sales growth was 3.5%, with 1.5% volume and 2.0% price growth. This profile converts EUR 50.5 billion at an estimated 2025 average EUR/USD rate of 1.0875 for USD comparison.
Company-Specific SWOT Notes
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
Unilever PLC
Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.
Unilever wins when trusted brands, local distribution, and repeat-purchase categories let it defend price premiums while reaching households at huge scale.
The biggest risk is that portfolio simplification and the Ice Cream demerger distract management while private labels and local challengers take share.
Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Unilever PLC | Unilever PLC reports the larger revenue base ($54.9B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Unilever PLC | Founded in 1996 vs 1929. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Novartis AG | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Unilever PLC | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novartis AG | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Unilever PLC reports the larger revenue base ($54.9B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1996 vs 1929. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novartis AG or Unilever PLC?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novartis AG vs Unilever PLC
Is Novartis AG better than Unilever PLC?
Verdict: Between Novartis AG and Unilever PLC, Unilever PLC is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Unilever PLC comes out ahead in this Novartis AG vs Unilever PLC comparison.
Who earns more — Novartis AG or Unilever PLC?
Unilever PLC earns more with $54.9B in annual revenue versus Novartis AG's $54.5B. Unilever PLC leads on total revenue based on latest verified figures.
Which company has higher revenue — Novartis AG or Unilever PLC?
Novartis AG reported $54.5B, while Unilever PLC reported $54.9B. The revenue leader is Unilever PLC based on latest verified figures.
Novartis AG revenue vs Unilever PLC revenue — which is higher?
Novartis AG revenue: $54.5B. Unilever PLC revenue: $54.5B. Unilever PLC has the larger revenue base of the two companies.
Sources & References
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com
- Unilever PLC Corporate Website
- Unilever PLC Annual Report 2025 - Revenue and Financial Data
- unilever.com
- unilever.com
- unilever.com
- unilever.com